Sun, Dec 28, 2014, 4:01 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

diaDexus, Inc. Message Board

  • biotuesday biotuesday Sep 17, 2013 8:50 AM Flag

    BioTuesdays: diaDexus awaiting GSK’s darapladib pivotal results

    Positive data from GlaxoSmithKline’s two pivotal trials of its darapladib cardiovascular drug could provide a huge boost to the utilization of diaDexus’ (OTCQB:DDXS) PLAC test, which is being used on patients in the studies to measure their levels of Lp-PLA2, a biomarker that identifies risk of heart attack and stroke.
    “If the darapladib trials are successful, it would mean that the Lp-PLA2 enzyme may be considered a risk factor for cardiovascular disease, which could increase utilization of the test by physicians and result in positive reimbursement decisions,” diaDexus president and CEO, Brian Ward, says in an interview with BioTuesdays.
    “The FDA also may require a companion diagnostic for GSK’s drug, and diaDexus has the worldwide distribution rights for the companion diagnostic,” he adds.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.51+0.07(+15.91%)Dec 26 3:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
Ocwen Financial Corp.
NYSEFri, Dec 26, 2014 4:03 PM EST